Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
combination drug therapy
immune checkpoint inhibitor
immune-related adverse event
non-small-cell lung cancer
retrospective study
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
11
2020
accepted:
03
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
10
4
2021
Statut:
epublish
Résumé
The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with the good clinical outcomes. However, the effects of immunotherapy plus chemotherapy remain unknown. In this study, we investigated the association between irAEs caused by immunotherapy plus chemotherapy and clinical efficacy in patients with advanced NSCLC. We retrospectively analyzed the data of patients with advanced NSCLC, who received a combination of immunotherapy plus chemotherapy at six institutions in Japan between January 2019 and September 2019. We examined the effect of irAEs on various clinical outcomes. We included 70 patients with advanced NSCLC. Patients were divided into two groups: patients with irAEs and patients without irAEs. Patients with irAEs had significantly longer progression-free survival than those without irAEs on univariate (hazard ratio 0.53, 95% confidence interval 0.30-0.93, p = 0.026) and multivariate (hazard ratio 0.53, 95% confidence interval 0.29-0.97, p = 0.041) analyses. In addition, patients with grade 1-2 irAEs (mild irAEs) had significantly longer progression-free and overall survival than those with grade 3-5 irAEs (severe irAEs) or without irAEs on univariate (398 days versus 189 days, respectively; p = 0.0061) and multivariate (not reached versus 412 days, respectively; p = 0.021) analyses. Patients with NSCLC who experienced mild irAEs showed better response to treatment with immunotherapy plus chemotherapy than those with severe irAEs or without irAEs. Further large-scale research is warranted to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with the good clinical outcomes. However, the effects of immunotherapy plus chemotherapy remain unknown. In this study, we investigated the association between irAEs caused by immunotherapy plus chemotherapy and clinical efficacy in patients with advanced NSCLC.
MATERIALS AND METHODS
METHODS
We retrospectively analyzed the data of patients with advanced NSCLC, who received a combination of immunotherapy plus chemotherapy at six institutions in Japan between January 2019 and September 2019. We examined the effect of irAEs on various clinical outcomes.
RESULTS
RESULTS
We included 70 patients with advanced NSCLC. Patients were divided into two groups: patients with irAEs and patients without irAEs. Patients with irAEs had significantly longer progression-free survival than those without irAEs on univariate (hazard ratio 0.53, 95% confidence interval 0.30-0.93, p = 0.026) and multivariate (hazard ratio 0.53, 95% confidence interval 0.29-0.97, p = 0.041) analyses. In addition, patients with grade 1-2 irAEs (mild irAEs) had significantly longer progression-free and overall survival than those with grade 3-5 irAEs (severe irAEs) or without irAEs on univariate (398 days versus 189 days, respectively; p = 0.0061) and multivariate (not reached versus 412 days, respectively; p = 0.021) analyses.
CONCLUSION
CONCLUSIONS
Patients with NSCLC who experienced mild irAEs showed better response to treatment with immunotherapy plus chemotherapy than those with severe irAEs or without irAEs. Further large-scale research is warranted to confirm these findings.
Identifiants
pubmed: 33833990
doi: 10.3389/fonc.2021.630136
pmc: PMC8021904
doi:
Types de publication
Journal Article
Langues
eng
Pagination
630136Informations de copyright
Copyright © 2021 Morimoto, Yamada, Takumi, Ogura, Takeda, Onoi, Chihara, Taniguchi, Yamada, Hiranuma, Morimoto, Iwasaku, Kaneko, Uchino and Takayama.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
ESMO Open. 2017 Mar 7;2(Suppl 1):e000119
pubmed: 29147577
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
JAMA Dermatol. 2015 Nov;151(11):1206-1212
pubmed: 26222619
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Oncol Pharm Pract. 2019 Oct;25(7):1645-1650
pubmed: 30319062
J Thorac Oncol. 2016 Nov;11(11):1927-1939
pubmed: 27496650
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187
pubmed: 32140762
Clin Lung Cancer. 2019 Jul;20(4):237-247.e1
pubmed: 30885550
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
BMC Med. 2020 Apr 20;18(1):87
pubmed: 32306958
Clin Lung Cancer. 2019 May;20(3):201-207
pubmed: 30442524
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Sci. 2019 Mar;110(3):1012-1020
pubmed: 30618179
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485
pubmed: 30506406
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Oncologist. 2020 Mar;25(3):e536-e544
pubmed: 32162801
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Lung Cancer. 2019 Jan;20(1):e97-e106
pubmed: 30337270
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856